 <h1>Malarone Pediatric Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>atovaquone / proguanil</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about atovaquone / proguanil. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Malarone Pediatric.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to atovaquone / proguanil: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, atovaquone/proguanil may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>Check with your doctor as soon as possible if any of the following side effects occur while taking atovaquone / proguanil:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, loosening of skin</li>
<li> chills</li>
<li>convulsions</li>
<li>difficulty swallowing</li>
<li>fast heartbeat</li>
<li> hives or welts</li>
<li>increased sensitivity of skin to sunlight</li>
<li>itching, redness or other discoloration of skin</li>
<li>joint or muscle pain</li>
<li> large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, sex organs</li>
<li>loss of bladder control</li>
<li>muscle spasm or jerking of all extremities</li>
<li> puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue </li>
<li>rash</li>
<li>red, irritated eyes </li>
<li>red skin lesions, often with a purple center</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>severe mental changes</li>
<li>severe sunburn </li>
<li>shortness of breath</li>
<li> skin rash</li>
<li>sores, ulcers or white spots in mouth or on lips</li>
<li>sudden loss of consciousness</li>
<li>tightness in chest</li>
<li>unusual tiredness or weakness</li>
<li>wheezing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of atovaquone / proguanil may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal pain</li>
<li>back pain</li>
<li>coughing</li>
<li>diarrhea</li>
<li> dreams</li>
<li>fever</li>
<li>headache </li>
<li>itching skin </li>
<li>lack of or loss of strength</li>
<li>nausea</li>
<li> muscle pain</li>
<li>sore throat</li>
<li> sores in mouth</li>
<li>sneezing</li>
<li> vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>blurred or loss of vision</li>
<li>disturbed color perception</li>
<li>dizziness</li>
<li> double vision</li>
<li>flu like symptoms</li>
<li> halos around lights</li>
<li>heartburn</li>
<li> indigestion</li>
<li>loss of appetite</li>
<li> night blindness</li>
<li>overbright appearance of lights </li>
<li>sleeplessness</li>
<li>stomach discomfort, upset or pain</li>
<li>trouble sleeping</li>
<li>tunnel vision</li>
<li>unable to sleep</li>
<li>weight loss</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Discouragement</li>
<li>fear</li>
<li> feeling sad or empty</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>nervousness</li>
<li> trouble concentrating</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to atovaquone / proguanil: oral tablet</i></p><h3>General</h3><p>In general, side effects associated with the use of atovaquone-proguanil have been mild.  Side effects are more pronounced and occur more frequently when higher doses are used in the treatment of malaria than with lower prophylactic doses.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic side effects have included pruritus (2%).  Cutaneous reactions ranging from rash, photosensitivity, and urticaria have been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects have included abdominal pain (5% to 17%), nausea (3% to 12%), vomiting (1% to 12%), diarrhea (4% to 8%), mouth ulcers (6%), anorexia (5%), dyspepsia (2%), and gastritis (2%).  GI upset has also been reported.  Stomatitis has been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatic side effects have included transient increases in liver function tests.  These increases have not required discontinuation of therapy.  Rare cases of hepatitis, cholestasis, and a single case of hepatic failure have been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Musculoskeletal side effects have included asthenia (8%), myalgia (7%), and back pain (4%).<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects have included headache (4% to 17%), dizziness (2% to 5%), vertigo (2%), and visual disturbances (2%).  Rare cases of seizures and psychotic events (such as hallucinations) have been reported during postmarketing experience.  However, a causal relationship has not been established.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory side effects have rarely included cough (4%).<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity side effects have included rare cases of anaphylaxis.  Rare cases of erythema multiforme, Stevens-Johnson syndrome, vasculitis, and angioedema have been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects including strange or vivid dreams (7%), insomnia (3%), anxiety (less than 1%), and depression (less than 1%) have been reported.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects including neutropenia, anemia (rarely), and pancytopenia in patients with severe renal impairment treated with proguanil have been reported during the postmarketing experience.</p><h3>Other</h3><p>Other side effects have included flu-like symptoms (4%) and fever (3%).<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Malarone (atovaquone-proguanil)" Glaxo Wellcome, Research Triangle Pk, NC. </p><p id="ref_2">2. Overbosch D,  Schilthuis H,  Bienzle U, et al. "Atovaquone-Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers: Results from a Randomized, Double-Blind Study." Clin Infect Dis 33 (2001): 1015-21</p><p id="ref_3">3. Winstanley P "Malaria: treatment." J R Coll Physicians Lond 32 (1998): 203-7</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Malarone Pediatric (atovaquone / proguanil)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Generic Availability</li>
<li>Drug class: antimalarial combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Malarone Pediatric &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Other Formulations</h3>
<ul class="more-resources-list more-resources-list-formulations">
<li>Malarone</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Malaria</li>
<li>Malaria Prevention</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to atovaquone / proguanil: oral tablet</i></p><h3>General</h3><p>In general, side effects associated with the use of atovaquone-proguanil have been mild.  Side effects are more pronounced and occur more frequently when higher doses are used in the treatment of malaria than with lower prophylactic doses.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic side effects have included pruritus (2%).  Cutaneous reactions ranging from rash, photosensitivity, and urticaria have been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects have included abdominal pain (5% to 17%), nausea (3% to 12%), vomiting (1% to 12%), diarrhea (4% to 8%), mouth ulcers (6%), anorexia (5%), dyspepsia (2%), and gastritis (2%).  GI upset has also been reported.  Stomatitis has been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatic side effects have included transient increases in liver function tests.  These increases have not required discontinuation of therapy.  Rare cases of hepatitis, cholestasis, and a single case of hepatic failure have been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Musculoskeletal side effects have included asthenia (8%), myalgia (7%), and back pain (4%).<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects have included headache (4% to 17%), dizziness (2% to 5%), vertigo (2%), and visual disturbances (2%).  Rare cases of seizures and psychotic events (such as hallucinations) have been reported during postmarketing experience.  However, a causal relationship has not been established.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory side effects have rarely included cough (4%).<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity side effects have included rare cases of anaphylaxis.  Rare cases of erythema multiforme, Stevens-Johnson syndrome, vasculitis, and angioedema have been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects including strange or vivid dreams (7%), insomnia (3%), anxiety (less than 1%), and depression (less than 1%) have been reported.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects including neutropenia, anemia (rarely), and pancytopenia in patients with severe renal impairment treated with proguanil have been reported during the postmarketing experience.</p><h3>Other</h3><p>Other side effects have included flu-like symptoms (4%) and fever (3%).<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Malarone (atovaquone-proguanil)" Glaxo Wellcome, Research Triangle Pk, NC. </p><p id="ref_2">2. Overbosch D,  Schilthuis H,  Bienzle U, et al. "Atovaquone-Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers: Results from a Randomized, Double-Blind Study." Clin Infect Dis 33 (2001): 1015-21</p><p id="ref_3">3. Winstanley P "Malaria: treatment." J R Coll Physicians Lond 32 (1998): 203-7</p><h2>More about Malarone Pediatric (atovaquone / proguanil)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Generic Availability</li>
<li>Drug class: antimalarial combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Malarone Pediatric &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Malarone</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Malaria</li>
<li>Malaria Prevention</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>